Breast Cancer: Targeting mutant estrogen receptors
A drug used in hormone replacement therapy can target estrogen receptors that have become resistant to breast cancer treatments.
- Duke University School of Medicine, United States
In three quarters of human breast cancers, the tumor cells have estrogen receptors and grow when exposed to this hormone. Most of these cancers will respond to drugs that target the activity of the receptor. For example, selective estrogen receptor modulators (SERMs) work by competing with estrogen and taking the hormone’s place on the receptor. Selective estrogen receptor downregulators (SERDs) behave in a similar way, but they can also trigger the degradation of the receptors.
The first breast cancer therapy targeting estrogen receptors to be approved in the United States was a SERM called tamoxifen, yet drugs that inhibit the production of estrogen have fewer side effects and are usually the first choice when treating patients with post-menopausal breast cancer. However, recent data suggest that mutations in estrogen receptors can reduce the effectiveness of these drugs. Such mutations are rare before cancer treatment, but they are found at a much higher rate in patients in which the disease has progressed (Toy et al., 2013).
The mutations most commonly associated with cancer spreading, Y537S and D538G, occur within the helix 12 subdomain, a region of the receptor that is exceptionally important for ligand pharmacology. The resistance caused by these mutations limits the therapeutic lifespan of cancer treatments, and highlights the importance of developing new SERMs and SERDs which can be used against tumors that stopped responding to drugs.
When estrogen binds to a wild-type receptor, the helix 12 subdomain folds and clamps the hormone in the ligand-binding pocket of the receptor (Figure 1A). At the same time, this change creates an interacting surface for coactivators, the proteins that cooperate with the receptor to activate gene transcription (Celik et al., 2007). However, the binding of a SERM changes the shape of the helix 12 subdomain in a way that inactivates the receptor by preventing its interaction with a coactivator. When a SERD occupies the receptor, the resulting modification of the helix 12 subdomain leads to the degradation of the receptor.
Figure 1
The Y537S mutation stabilizes the estrogen receptor and interferes with the action of drugs.
(A) In the absence of a ligand, the helix 12 subdomain (blue-green cylinder) of the wild-type estrogen receptor (WT ERα, orange structure) is flexible. As the receptor binds estrogen (green sphere), the helix 12 subdomain folds in a way that allows coactivator proteins (purple blue cylinder) to attach to the receptor. When the ligand-binding domain is occupied by a SERM (red sphere), the helix 12 subdomain is repositioned and occludes the activation surface, which inhibits the receptor. Treatment with a SERD (dark blue ovoid) destabilizes the helix 12 subdomain, leading to the degradation of the receptor. When the receptor is exposed to hybrid SERM/SERD molecules, such as bazedoxifene (BZA), the helix 12 subdomain can adopt either SERM or SERD conformations (black arrows): the receptor is continuously inhibited, even though it is inefficiently degraded. (B) The mutation Y537S (asterisk) stabilizes the helix 12 subdomain in the active conformation, which activates the receptor even in the absence of estrogen (left). When treated with a SERM or SERD, the mutant receptor can adopt conformations similar to the ones observed when the wild-type receptor is bound to these drugs. However, the mutation lowers the affinity of the mutant receptor for SERMs and SERDs; even after treatment with these drugs, unliganded receptors that are active can be present. The SERM/SERD hybrid drug bazedoxifene has a high enough affinity that it can bind to and fully inhibit the mutant receptor, making it adopt the SERM-associated conformation. However, it does not efficiently cause the mutant receptor to adopt the SERD conformation (dotted arrow); this can therefore result in the mutant receptor being inhibited, but not degraded. Image credit: Suzanne E Wardell (CC BY 4.0).
Experiments also showed that Y537S and D538G mutations stabilize the unliganded receptor, and allow the helix 12 subdomain to adopt an active conformation: the mutant receptors are activated even in the absence of estrogen (Fanning et al., 2016; Figure 1B). These mutations also reduce the affinity of the receptors for their hormone and for most SERMs and SERDs. Therefore, even in the presence of the SERMs or SERDs currently used in breast cancer treatment, the receptor favors the active conformation. Now, in eLife, Geoffrey Greene of the University of Chicago and colleagues in the US and the Netherlands – including Sean Fanning as first author – report how a hybrid SERM/SERD drug can overcome the resistance conferred by mutant receptors (Fanning et al., 2018).
Hybrid SERM/SERD molecules, such as the drug bazedoxifene, display exceptional inhibitory activities in tumor models, but they degrade estrogen receptors very inefficiently. Fanning et al. address this long-standing paradox, and demonstrate that bazedoxifene allows the helix 12 subdomain to align in two distinct orientations: one replicates the inactive conformation observed when the receptor binds to a classical SERM, and the other mimics the unstable structure found when a classical SERD occupies the receptor. However, estrogen receptors with the Y537S and D538G mutations are more stable: when they are bound to bazedoxifene, they primarily adopt the SERM-associated conformation, rather than the one observed with SERDs. Although the mutant receptor is then not degraded, it remains efficiently inhibited in this inactive conformation.
Bazedoxifene is a well-characterized modulator of estrogen receptors, and it is currently used in hormone replacement therapy and to treat post-menopausal osteoporosis (Kawate and Takayanagi, 2011; Komm et al., 2014). While recently developed SERDs have struggled with clinical setbacks due to intolerability, this drug has been thoroughly tested in patients and is both safe and tolerable. Intense efforts are underway to identify new drugs that target estrogen receptors, and some interesting new molecules have already emerged, but they are not likely to be approved for clinical use for several years. Prior studies have shown that bazedoxifene can reduce estrogen receptors within tumors, albeit with less efficiency than other benchmark SERD drugs. Bazedoxifene can also inhibit the growth of tumors derived from patients that carry mutations in their estrogen receptors (Wardell et al., 2013; Wardell et al., 2015). These data raise the possibility that the compound might be of some clinical utility in breast cancer treatment.
The work by Fanning et al. describes the mechanisms by which bazedoxifene inhibits estrogen receptors, and offers guidance for the development of new treatments for breast cancer. Although the drug is likely to help control cancers that have progressed during treatment, independent of mutant status, its utility may be limited by patent life; there clearly remains an unmet medical need for new molecules that can effectively inhibit and degrade clinically relevant mutations of the receptors.
References
-
Efficacy and safety of bazedoxifene for postmenopausal osteoporosisClinical Interventions in Aging 6:151–160.https://doi.org/10.2147/CIA.S15711
-
ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics 45:1439–1445.https://doi.org/10.1038/ng.2822
Article and author information
Author details
Donald P McDonnell
Publication history
Copyright
© 2019, Wardell et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,315
- views
-
- 229
- downloads
-
- 5
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Breast Cancer: Targeting mutant estrogen receptors
eLife 8:e44181.
https://doi.org/10.7554/eLife.44181
Further reading
-
- Cancer Biology
- Immunology and Inflammation
The current understanding of humoral immune response in cancer patients suggests that tumors may be infiltrated with diffuse B cells of extra-tumoral origin or may develop organized lymphoid structures, where somatic hypermutation and antigen-driven selection occur locally. These processes are believed to be significantly influenced by the tumor microenvironment through secretory factors and biased cell-cell interactions. To explore the manifestation of this influence, we used deep unbiased immunoglobulin profiling and systematically characterized the relationships between B cells in circulation, draining lymph nodes (draining LNs), and tumors in 14 patients with three human cancers. We demonstrated that draining LNs are differentially involved in the interaction with the tumor site, and that significant heterogeneity exists even between different parts of a single lymph node (LN). Next, we confirmed and elaborated upon previous observations regarding intratumoral immunoglobulin heterogeneity. We identified B cell receptor (BCR) clonotypes that were expanded in tumors relative to draining LNs and blood and observed that these tumor-expanded clonotypes were less hypermutated than non-expanded (ubiquitous) clonotypes. Furthermore, we observed a shift in the properties of complementarity-determining region 3 of the BCR heavy chain (CDR-H3) towards less mature and less specific BCR repertoire in tumor-infiltrating B-cells compared to circulating B-cells, which may indicate less stringent control for antibody-producing B cell development in tumor microenvironment (TME). In addition, we found repertoire-level evidence that B-cells may be selected according to their CDR-H3 physicochemical properties before they activate somatic hypermutation (SHM). Altogether, our work outlines a broad picture of the differences in the tumor BCR repertoire relative to non-tumor tissues and points to the unexpected features of the SHM process.
-
- Cancer Biology
- Computational and Systems Biology
Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.
